25 results about "Lid margin" patented technology

To improve the consistency of performance of a contact lens between wearers.SOLUTION: An ophthalmic lens may include a first surface. The exemplary ophthalmic lens may include a second surface disposed opposite the first surface and defining a volume of lens material between the first surface and the second surface. A thickness profile of the volume of lens material may be derived from the one or more eyelid profiles such that a thickness gradient of the volume of lens material is oriented substantially orthogonal to the target eyelid margin shape.SELECTED DRAWING: Figure 1

The present invention is in the field of ocular disease therapy. In particular, the invention relates to a composition comprising pimecrolimus for use in the topical treatment of moderate to severe blepharitis, in particular in a patient group comprising subjects with a clinical diagnosis of moderate to severe blepharitis, wherein the subjects to be treated have signs and symptoms of moderate to severe blepharitis characterised by swelling of the eyelid margin, ocular debris and ocular discomfort. In particular, the present invention relates to an ophthalmic composition that shows a high patient acceptance and a clinically meaningful improvement in the signs and symptoms of treated patients.

Described herein are compositions and methods for treating or preventing skin or ocular surface disorders, such as those associated with bacterial and / or parasitic infections. Bacterial and / or parasitic infections include mites (e.g., Demodex), helminths, protozoa (e.g., amebas (e.g., Acanthamoeba or Cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. The compositions and methods include compounds that exhibit immunological activity, keratolytic activity, antihistamine activity, anti-inflammatory activity, and / or other desirable activities. Topical administration of the compositions to the eyelid margin or surrounding area provides therapeutic benefit to patients with ocular surface disorders.

Disclosed are ophthalmic compositions for removing biofilms from the eye and for treating inflammation, blepharitis and dry eye of the eye, the ophthalmic compositions comprising an alpha-amylase and optionally other ingredients. The blepharitis is inflammation of eyelids and areas around the eyelids. The blepharitis generally affects both eyes, including areas along the edges of the eyelids. The blepharitis is considered to occur when tiny oil glands near the roots of the eyelashes become clogged, causing stimulation and redness. Several diseases and conditions may be associated with blepharitis.

A method and apparatus for treating ocular disorders such as blepharitis, meibomitis, and dry eye syndrome. The method includes using an electromechanical device to move a swab relative to the eye to create cyclical movement that impacts debris present at the eyelid margin and effectively removes the debris from the eye to encourage healing and prevent further digression of the health of the eye. The apparatus is an electromechanical device that includes a mechanical drive unit operatively connected to a swab to create a precise relative movement of the swab to the eye to remove debris present therein.

This invention relates to the field of image edge detection technology, specifically to an eyelid detection system for assessing the orbicularis oculi muscle movement function in patients with myasthenia gravis. The system includes a video frame acquisition module, an iris morphology reconstruction module, an interference level acquisition module, a gradient map correction module, and an eyelid edge detection module. By acquiring video frame data of the patient's eyes, the system corrects iris deformation in the iris region of the target image frame corresponding to eye movement. Based on the corrected iris region, the system analyzes the interference of iris morphology on eyelid edge detection, determines the degree of iris deformation interference, and then corrects the gradient values ​​of gradient points in the same area corresponding to the corrected iris region in the gradient map of the target image frame during eye movement, obtaining a corrected gradient map. Based on the corrected gradient map, the system determines the patient's eyelid edge detection result. This invention effectively improves the accuracy of eyelid edge detection for patients.

To suppress invasiveness and improve comfort for the patient. 【Solution means】 The device massages the eyelid to move the meibomian gland in one direction through the meibomian gland duct towards the gland duct orifice at the eyelid margin in order to remove the meibomian gland duct blockage within the gland duct. The device is configured to periodically apply pressure to the application area of the eyelid, move the applied pressure in the flow direction towards the gland duct orifice, and release the pressure applied to the application area of the eyelid. This device includes an elongated massage arm configured to support a massage tip configured to apply pressure to the application area of the eyelid. The cam is rotatable about a rotation axis and includes a cam surface. The follower includes a follower surface that slidably engages with the cam surface. The follower is configured to impart a massage motion to the massage arm in response to the rotation of the cam. The cam surface has a curved configuration of a constant width. The cam is configured such that the center of the cam surface is offset from the rotation axis of the cam.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

The present disclosure provides an ophthalmic formulation comprising: one or more pharmaceutically acceptable excipients; a pharmaceutically active compound capable of reducing the amount or deleterious effects of autoantibodies on the ocular surface, such as IgG; in particular, the present disclosure provides an ophthalmic formulation wherein the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular diseases that can cause symptoms of ocular discomfort, keratitis, dry eye disease, formation of symblepharon, shortening of the anterior chamber depth, lid margin / conjunctival keratinization, subconjunctival fibrosis, retinal gliosis and glaucoma.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

Blepharitis, an infection and inflammation of the edge of the eyelids, and meibomian gland dysfunction (MGD), blockage of tiny oil glands at the eye lid margin, are quite common, usually under diagnosed and underappreciated diseases. There are number of causes for blepharitis, including bacterial components such as Staphylococcus aureus, Staphylococcus epidermidis, Propionibacterium acnes and Corynebacteria sp., seborrhea or microscopic mites (Demodex). More than 50% of patients seeking ophthalmologic consultations have symptoms and signs indicating one of these entities. Another large number of patients remain undiagnosed or in early stages of disease that could be easily treated thus preventing long-term pain and suffering. MGD is in fact the leading cause of dry eye disease, a potentially preventable malady.

The application discloses an AI analysis-based tear film state monitoring system and an intelligent glasses dry eye early warning method, relates to the technical field of image processing, and comprises a pattern projection module, an ocular surface image acquisition module and a highlight suppression image generation module; the AI analysis-based tear film state monitoring system provided in the application collects eyelid edge region images by projecting a near-infrared laser speckle pattern, uses the near-infrared laser speckle pattern as a source texture, and generates a highlight suppression image by predicting a distortion field to guide the deformation of the source texture, thereby completing highlight repair; the feature information loss problem caused by the non-fixed position of the highlight reflected by the tear meniscus mirror is relieved, and stable imaging of the meibomian gland opening area under a dynamic ocular surface environment is realized.

Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders, such as those associated with bacterial and / or parasitic infections. Bacterial and / or parasitic infections include mites (e.g., demodex), worms, protozoa (e.g., amoeba (e.g., acanthamoeba or cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. Said compositions and methods comprise compounds which demonstrate immunological, keratolytic, anti-histamine, anti-inflammatory, and / or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

The invention provides an appliance and a method for assisting in use of eye drops, the appliance comprises a connecting handle, the connecting handle comprises two U-shaped structures, the opening ends of the two U-shaped structures are oppositely closed, the two U-shaped structures respectively correspond to a first U-shaped structure of a long handle and a second U-shaped structure of a short handle, and an opening of the first U-shaped structure is connected with an opening of the second U-shaped structure through a rotating shaft in a penetrating manner; a reset spring is arranged on the outer ring of the rotating shaft, and the bottom plate of each U-shaped structure is located at the connecting position of the side wing and the lower wing on the corresponding side. The ends, away from the U-shaped structure bottom plate, of the side wings are sequentially connected with pinching side lugs and supporting rings, an inverted eye drop bottle body is clamped between the two supporting rings, and an eyelid edge contact plate is arranged at the end, away from the side wings, of the lower wing. The reset spring is installed on the outer ring of the rotating shaft, the two extending ends of the reset spring abut against the connecting positions of the side wings and the lower wings on the two sides respectively, the lever mechanics principle and the resilience mechanics principle are fused, and the use efficiency and effect of the device are ensured.

An eye care device that is operable to absorb tears and similar liquid from an eye wherein the device is provided in a disposable format. The device includes a lower portion integrally formed with an upper portion. The lower portion is planar in manner having a first side and a second side. The upper portion is manufactured from an absorbent lint free material such as but not limited any combination of polyamide, polyester, polypropylene or medical grade cellulose fibers. The upper portion of the present invention includes a bulbously formed middle section that tapers into the upper end of the lower portion. The top section of the upper portion has a precisely formed tip member that reaches the meniscus at the lid margin of the eye without contacting the cornea. The outer surface has disposed thereon a multitude of porous channels that wick tears by capillary action.

Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders, such as those associated with bacterial and / or parasitic infections. Bacterial and / or parasitic infections include mites (e.g., demodex), worms, protozoa (e.g., amoeba (e.g., acanthamoeba or cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. Said compositions and methods comprise compounds which demonstrate immunological, keratolytic, anti-histamine, anti-inflammatory, and / or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

The present invention relates to isocyclosporin A, salts and ophthalmic compositions thereof for ophthalmic topical use in the prevention or treatment in an individual of an ophthalmic inflammatory and / or autoimmune disease, preferably selected from corneal and ocular surface inflammatory and / or autoimmune diseases and eyelid margin inflammatory diseases.

This utility model discloses a meibomian gland model, including a support assembly, an adsorption element at the bottom, and a detachable demonstration assembly at the top. The support assembly is height-adjustable, allowing it to move up and down. The demonstration assembly includes an eyeball demonstration element, which is partially covered by an eyelid edge demonstration element. Several gland demonstration elements are located on the eyelid edge demonstration element. The upper and lower eyelid demonstration elements are combined to form an openable shell, enclosing the eyeball demonstration element, eyelid edge demonstration element, and gland demonstration element. The upper, lower, and upper eyelid demonstration elements are made of elastic material. The lower eyelid demonstration element forms several channels, within which extrusion demonstration elements are retractable. Pressing the lower eyelid demonstration element causes the extrusion demonstration elements to extend out of the channels. This utility model facilitates the disassembly and display of the internal meibomian gland structure, which is beneficial for teaching, observation, and research.

Ophthalmic device (1) for in vivo application on the eyeball of an eye (14), in particular a human eye (14), comprising: - a ring body (2) with an outer circumferential surface (3) coaxial to its central axis (M), wherein a first end face (4) of the ring body (2) is designed for placing the ring body (2) on the eyeball, in particular in the area of ​​the iris when the eyelids (17) are open; and - a handle element (5) that is operatively coupled or can be coupled to the ring body (2) for handling the ophthalmic device (1); and - one or more under-engaging tabs (6) which project radially outwards at the frontal end (4) of the ring body (2) with respect to the central axis (M), and are designed to engage an eyelid margin (17) of the eye (15) when the ring body (2) is placed on it.

A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.

Ophthalmic lenses are described herein. An example ophthalmic lens may comprise a first surface. The example ophthalmic lens may comprise a second surface disposed opposite the first surface and defining a volume of lens material therebetween. A thickness profile of the volume of lens material may be derived from one or more eyelid profiles such that a thickness gradient of the volume of lens material is oriented to be substantially orthogonal to a target eyelid margin shape.

The invention discloses an eyelid tractor for eye surgery. The eyelid tractor comprises a multi-point supporting traction component and a sliding fixing frame piece. The invention belongs to the field of medical instruments, and particularly relates to an eyelid tractor for eye surgery. According to the eye speculum, through mutual cooperation between the double-side sliding traction piece and the fixed main traction piece, on the basis of a traditional double-hook mode, a multi-point contact mode is added, pressure is dispersed, multi-point supporting is carried out along the edge of an eyelid, single-point concentrated pressing is avoided, and the situations of eyelash injury and eyelid extravasated blood are reduced; the comfort level is higher, the injury is smaller, and the surgical visual field of a doctor is better adapted.

Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders. Ocular surface disorders include ocular allergy, dry eye disease, ocular manifestation of graft versus host disease and other inflammatory and / or infectious diseases of the (e.g., anterior) surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate immunological, keratolytic, anti-inflammatory, and / or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

The present invention relates to isocyclosporin A, salts and ophthalmic compositions thereof for ophthalmic topical use in the prevention or treatment in an individual of an ophthalmic inflammatory and / or autoimmune disease, preferably selected from corneal and ocular surface inflammatory and / or autoimmune diseases and eyelid margin inflammatory diseases.